Protalix Biotherapeutics (PLX) Cut to “Strong Sell” at BidaskClub

BidaskClub lowered shares of Protalix Biotherapeutics (NYSEAMERICAN:PLX) from a sell rating to a strong sell rating in a research report report published on Saturday morning.

A number of other equities research analysts have also recently weighed in on the company. HC Wainwright set a $5.00 price objective on Protalix Biotherapeutics and gave the stock a buy rating in a research note on Wednesday, November 29th. Zacks Investment Research cut Protalix Biotherapeutics from a buy rating to a hold rating in a research note on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $3.00.

Shares of Protalix Biotherapeutics (NYSEAMERICAN:PLX) opened at $0.68 on Friday. Protalix Biotherapeutics has a 1-year low of $0.26 and a 1-year high of $1.51.

Protalix Biotherapeutics (NYSEAMERICAN:PLX) last issued its earnings results on Wednesday, November 8th. The company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.04). The business had revenue of $7.53 million during the quarter, compared to analyst estimates of $6.65 million. During the same period last year, the company earned ($0.07) EPS.

Several hedge funds have recently made changes to their positions in PLX. Renaissance Technologies LLC increased its holdings in shares of Protalix Biotherapeutics by 302.1% in the first quarter. Renaissance Technologies LLC now owns 1,927,500 shares of the company’s stock valued at $2,621,000 after purchasing an additional 1,448,200 shares during the period. Virtu KCG Holdings LLC acquired a new position in shares of Protalix Biotherapeutics in the second quarter valued at about $591,000. Finally, OxFORD Asset Management LLP acquired a new position in shares of Protalix Biotherapeutics in the second quarter valued at about $576,000.

WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at

About Protalix Biotherapeutics

Protalix BioTherapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers taliglucerase alfa for injection, which is an enzyme replacement therapy for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease.

Receive News & Ratings for Protalix Biotherapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix Biotherapeutics Inc and related companies with's FREE daily email newsletter.

Leave a Reply